These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7868973)

  • 1. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy.
    Pfohl M; Naoumova RP; Klass C; Knisel W; Jakober B; Risler T; Thompson GR
    J Lipid Res; 1994 Nov; 35(11):1946-55. PubMed ID: 7868973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
    Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
    Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of cholesterol synthesis after acute reduction of low density lipoprotein by apheresis in normocholesterolaemic subjects: evidence for a threshold effect.
    Pfohl M; Naoumova RP; Neuwirth C; Sussekov A; Smykowski J; Rendell NB; Taylor GW; Seif FJ; Thompson GR
    Atherosclerosis; 1997 Dec; 135(2):257-62. PubMed ID: 9430376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
    Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K
    Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.
    Marais AD; Naoumova RP; Firth JC; Penny C; Neuwirth CK; Thompson GR
    J Lipid Res; 1997 Oct; 38(10):2071-8. PubMed ID: 9374129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of severe familial heterozygous hypercholesterolemia by low-density lipoprotein apheresis with immunoadsorption: effects of the addition of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to therapy.
    Jacob BG; Richter WO; Schwandt P
    Clin Investig; 1993 Nov; 71(11):908-12. PubMed ID: 8312683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A; Harada-Shiba M; Kawaguchi A; Oi K; Kubo H; Sakai S; Mikami Y; Imai T; Ito T; Kato H; Endo M; Sato I; Suzuki Y; Hori H
    Atherosclerosis; 2000 Nov; 153(1):89-98. PubMed ID: 11058703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia.
    Thiery J; Seidel D
    Transfus Sci; 1993 Jul; 14(3):249-59. PubMed ID: 10146336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia.
    Zwiener RJ; Uauy R; Petruska ML; Huet BA
    J Pediatr; 1995 May; 126(5 Pt 1):728-35. PubMed ID: 7751996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New strategies in treatment of severe hypercholesterolemia in coronary patients: HMG-CoA reductase inhibitors and H.E.L.P.-LDL apheresis].
    Thiery J; Seidel D
    Versicherungsmedizin; 1992 Dec; 44(6):186-92. PubMed ID: 1475888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels.
    Kroon AA; van't Hof MA; Demacker PN; Stalenhoef AF
    Atherosclerosis; 2000 Oct; 152(2):519-26. PubMed ID: 10998482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.
    Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T
    Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia.
    Richter WO; Donner MG; Höfling B; Schwandt P
    Metabolism; 1998 Jul; 47(7):863-8. PubMed ID: 9667236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical experience with HELP-LDL-apheresis in combination with HMG-CoA-reductase inhibitors for maximum treatment of coronary heart disease associated with severe hypercholesterolemia.
    Eisenhauer T; Armstrong VW; Schuff-Werner P; Schütz E; Thiery J; Scheler F; Seidel D
    ASAIO Trans; 1989; 35(3):580-3. PubMed ID: 2597539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis.
    Nenseter MS; Narverud I; Græsdal A; Bogsrud MP; Aukrust P; Retterstøl K; Ose L; Halvorsen B; Holven KB
    J Clin Lipidol; 2013; 7(2):109-16. PubMed ID: 23415429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Removal of low density lipoproteins on dextrans sulfate in 2 patients with familial monogenic hypercholesterolemia].
    Aubert I; Bombail D; Erlich D; Goy-Loeper J; Chanu B; Bussel A; Rouffy J
    Ann Med Interne (Paris); 1988; 139 Suppl 1():72-6. PubMed ID: 2470281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of selective LDL-apheresis and pravastatin therapy on platelet function in familial hypercholesterolaemia.
    Bröijersén A; Eriksson M; Larsson PT; Beck O; Berglund L; Angelin B; Hjemdahl P
    Eur J Clin Invest; 1994 Jul; 24(7):488-98. PubMed ID: 7957507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current status of low-density lipoprotein apheresis.
    Borberg H; Kadar J; Oette K
    Curr Stud Hematol Blood Transfus; 1990; (57):239-48. PubMed ID: 2272204
    [No Abstract]   [Full Text] [Related]  

  • 19. The Effect of LDL-Apheresis and Rheohaemapheresis Treatment on Vitamin E.
    Solichová D; Bláha M; Aufartová J; Krcmová LK; Plíšek J; Honegrová B; Kasalová E; Lánská M; Urbánek L; Sobotka L
    J Nutr Sci Vitaminol (Tokyo); 2015; 61(2):105-12. PubMed ID: 26052140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL-apheresis angioplasty restenosis trial (L-ART).
    Yamaguchi H; Lee YJ; Daida H; Yokoi H; Miyano H; Kanoh T; Ishiwata S; Kato K; Nishikawa H; Takatsu F
    Chem Phys Lipids; 1994 Jan; 67-68():399-403. PubMed ID: 8187240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.